Get the Stockscreener App
2.24
5.49%
-0.13
Century Therapeutics Inc stock is traded at $2.24, with a volume of 1.76M.
It is down -5.49% in the last 24 hours and up +5.16% over the past month.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
See More
Previous Close:
$2.37
Open:
$2.37
24h Volume:
1.76M
Relative Volume:
0.91
Market Cap:
$402.58M
Revenue:
$109.16M
Net Income/Loss:
$-9.57M
P/E Ratio:
-21.29
EPS:
-0.1052
Net Cash Flow:
$-104.72M
1W Performance:
-2.18%
1M Performance:
+5.16%
6M Performance:
+362.33%
1Y Performance:
+283.76%
1-Day Range:
$2.155
$2.37
1-Week Range:
$2.155
$2.655
52-Week Range:
$0.3418
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.24 | 402.58M | 109.16M | -9.57M | -104.72M | -0.1052 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | TD Cowen | Buy |
| Aug-08-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Downgrade Watch: Will Century Therapeutics Inc benefit from seasonality2026 Dividend Review & Breakout Confirmation Alerts - baoquankhu1.vn
Century Therapeutics reports 2025 results, advances cell therapy pipeline - MSN
Fed Meeting: Will Arch Capital Group Ltd outperform small cap indexes2026 Buyback Activity & Real-Time Volume Surge Alerts - baoquankhu1.vn
Dip Buying: How sensitive is Century Therapeutics Inc to inflationQuarterly Market Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline - MyChesCo
Century Therapeutics Hits New 52-Week High at $2.95 - Markets Mojo
Century Therapeutics Hits New 52-Week High of $3.04 Amid Market Fluctuations - Markets Mojo
Century Therapeutics (NASDAQ:IPSC) Insider Sells $25,693.80 in Stock - MarketBeat
Century Therapeutics (NASDAQ:IPSC) SVP Sells $17,959.65 in Stock - MarketBeat
Century Therapeutics (IPSC) SVP sells 7,043 shares to cover tax withholding - Stock Titan
Century Therapeutics (IPSC) officer sells shares to cover tax - Stock Titan
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Growth in Short Interest - MarketBeat
Zacks Research Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
Century Therapeutics (IPSC) CEO has 55,397 shares withheld for RSU taxes - Stock Titan
Century Therapeutics (IPSC) CSO has 1,431 shares withheld for RSU tax obligations - Stock Titan
Century Therapeutics (IPSC) Receives a Buy from Clear Street - The Globe and Mail
Century Therapeutics (NASDAQ:IPSC) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Lantheus (LNTH), Century Therapeutics (IPSC) - The Globe and Mail
Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives - simplywall.st
IPSC (NASDAQ: IPSC) plans sale of 10,076 vested shares via Fidelity - Stock Titan
Century Therapeutics, Inc. announced that it has received $134.997458 million in funding from a group of investors - marketscreener.com
Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Century Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Century Therapeutics Reports 2025 Results and Pipeline Progress - TipRanks
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates - Investing News Network
CENTURY THERAPEUTICS ($IPSC) Releases Q4 2025 Earnings - Quiver Quantitative
Century Therapeutics 10-K Summary — Revenue: $— | EPS: $— - TradingView
Century Therapeutics 2025 net loss narrows beating estimates - TradingView
Century Therapeutics (NASDAQ: IPSC) slashes 2025 net loss on $109M revenue - Stock Titan
BRIEF-Century Therapeutics FY Net Income USD -9.58 Million - TradingView
Bearish Setup: Is Century Therapeutics Inc undervalued by DCF analysis2026 Catalysts & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Century Therapeutics (IPSC) officer auto-sells shares to cover RSU tax - Stock Titan
Century Therapeutics (IPSC) SVP Carr auto-sells shares to cover RSU tax - Stock Titan
Century Therapeutics (IPSC) to Release Quarterly Earnings on Wednesday - MarketBeat
Century Therapeutics (IPSC) CEO reports 463-share tax withholding on RSU vesting - Stock Titan
[144] Century Therapeutics, Inc. SEC Filing - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Raised to "Hold" at Wall Street Zen - MarketBeat
Piper Sandler highlights Century Therapeutics (IPSC) cash runway through 2029, upcoming IND submission - MSN
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting - MSN
IPSC Financials: Income Statement, Balance Sheet & Cash Flow | Century Therapeutics, Inc. - Stock Titan
Should I buy Century Therapeutics Inc stock nowJuly 2025 Final Week & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 39.8% in February - MarketBeat
IPSC SEC FilingsCentury Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Closing: How does Century Therapeutics Inc perform in inflationary periodsDollar Strength & Entry Point Confirmation Signals - baoquankhu1.vn
Century Therapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Century Therapeutics (NASDAQ:IPSC) Coverage Initiated by Analysts at TD Cowen - Defense World
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and Century Therapeutics (IPSC) - The Globe and Mail
Movement Recap: Is Century Therapeutics Inc forming a bullish divergenceQuarterly Portfolio Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Century Therapeutics to Participate in Upcoming Investor Conferences in March - Investing News Network
Century Therapeutics (NASDAQ:IPSC) Now Covered by Analysts at TD Cowen - MarketBeat
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.80%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):